Data from an on-going collaboration between Immodulon Therapeutics and the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation research (University of Manchester, Manchester UK) demonstrating the immunomodulatory effects of IMM-101 was presented at the 33rd Annual Conference of the European Macrophage & Dendritic Cell Society (EMDS) in Verona 27th to 29th September 2018 by Alicia A Gladon. These data show that IMM-101 activates dendritic cells and that such activated dendritic cells results in a typical Type I immune response with the generation of large numbers of different IFNγ producing immune cells, including cytotoxic T lymphocytes (CTLs) and natural killer cells (NKs). IFNγ cytokines and CTLs and NKs are well known to be crucial in efficient anti-cancer immune responses and these results assist in explaining IMM-101’s mechanism of action and its promising efficacy shown in advanced melanoma and pancreatic patients.
Full Title: Defining the immunomodulatory effects of IMM-101: a promising, novel co-therapy for cancer.
Authors: Alicia A Galdon, James Crooks, Sheila L Brown, Jaap Kampinga, Laura Rosa Brunet and Andrew S MacDonald.